Edwards Lifesciences Corp (EW)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $61.61B
Last updated: Nov 17, 2026 at 11:06 AM ET
Edwards Lifesciences Corp (EW) Earnings: Report Dates and Results
Edwards Lifesciences (EW) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Edwards Lifesciences reported EPS of $0.80, above the $0.73 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
EW has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.0% above the $0.58 reported for the quarter ended Dec 31, 2025.
EW Earnings Call
The latest EW earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, EW beat 30, missed 7 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $1.72B, up 11.0% from $1.55B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.80 | $0.73 | $0.72 - $0.77 | +9.59% | Beat | +19.4% | 24 | 0 up, 1 down | Nov 4, 2026 | $1.72B |
| Jun 30, 2026 | $0.78 | $0.73 | $0.73 - $0.76 | +6.85% | Beat | +16.4% | 22 | 1 up, 1 down | Jul 23, 2026 | $1.74B |
| Mar 31, 2026 | $0.78 | $0.73 | $0.71 - $0.75 | +6.85% | Beat | +21.9% | 24 | 13 up, 2 down | Apr 23, 2026 | $1.65B |
| Dec 31, 2025 | $0.58 | $0.62 | $0.60 - $0.65 | -6.39% | Miss | -1.7% | 27 | 6 up, 2 down | Feb 10, 2026 | $1.57B |
| Sep 30, 2025 | $0.67 | $0.59 | $0.57 - $0.62 | +13.56% | Beat | 0.0% | 25 | 6 up, 1 down | Oct 30, 2025 | $1.55B |
| Jun 30, 2025 | $0.67 | $0.62 | $0.60 - $0.65 | +8.06% | Beat | -4.3% | 26 | 1 up, 0 down | Jul 24, 2025 | $1.53B |
| Mar 31, 2025 | $0.64 | $0.60 | $0.57 - $0.64 | +6.67% | Beat | -3.0% | 26 | 0 up, 1 down | Apr 23, 2025 | $1.41B |
| Dec 31, 2024 | $0.59 | $0.55 | $0.53 - $0.64 | +6.38% | Beat | -7.8% | 27 | 1 up, 1 down | Feb 11, 2025 | $1.39B |
| Sep 30, 2024 | $0.67 | $0.59 | $0.54 - $0.70 | +13.56% | Beat | +13.6% | 26 | 1 up, 1 down | Oct 24, 2024 | $1.35B |
| Jun 30, 2024 | $0.70 | $0.69 | $0.67 - $0.71 | +1.45% | Beat | +6.1% | 26 | 2 up, 1 down | Jul 24, 2024 | $1.37B |
| Mar 31, 2024 | $0.66 | $0.64 | $0.63 - $0.66 | +3.13% | Beat | +6.5% | 25 | 0 up, 1 down | Apr 25, 2024 | $1.33B |
| Dec 31, 2023 | $0.64 | $0.64 | $0.62 - $0.67 | 0.00% | In line | 0.0% | 25 | 1 up, 0 down | Feb 6, 2024 | $1.01B |
| Sep 30, 2023 | $0.59 | $0.59 | $0.57 - $0.61 | 0.00% | In line | -3.3% | 25 | 0 up, 0 down | Oct 25, 2023 | $1.24B |
| Jun 30, 2023 | $0.66 | $0.65 | $0.62 - $0.66 | +1.54% | Beat | +4.8% | 23 | 1 up, 0 down | Jul 26, 2023 | $1.30B |
| Mar 31, 2023 | $0.62 | $0.61 | $0.55 - $0.64 | +1.64% | Beat | +3.3% | 22 | 0 up, 0 down | Apr 26, 2023 | $1.46B |
| Dec 31, 2022 | $0.64 | $0.61 | $0.57 - $0.63 | +4.92% | Beat | +25.5% | 22 | 0 up, 1 down | Jan 31, 2023 | $429.90M |
| Sep 30, 2022 | $0.61 | $0.62 | $0.61 - $0.65 | -1.61% | Miss | +13.0% | 23 | 0 up, 1 down | Oct 27, 2022 | $1.32B |
| Jun 30, 2022 | $0.63 | $0.64 | $0.62 - $0.66 | -1.56% | Miss | -1.6% | 20 | 1 up, 1 down | Jul 28, 2022 | $1.37B |
| Mar 31, 2022 | $0.60 | $0.57 | $0.55 - $0.60 | +5.26% | Beat | +11.1% | 24 | 1 up, 0 down | Apr 26, 2022 | $1.34B |
| Dec 31, 2021 | $0.51 | $0.55 | $0.53 - $0.57 | -7.27% | Miss | +2.0% | 22 | 0 up, 0 down | Jan 26, 2022 | $1.33B |
| Sep 30, 2021 | $0.54 | $0.53 | $0.51 - $0.56 | +1.89% | Beat | +5.9% | 23 | 0 up, 1 down | Oct 27, 2021 | $1.31B |
| Jun 30, 2021 | $0.64 | $0.55 | $0.50 - $0.64 | +16.36% | Beat | +88.2% | 24 | N/A | Jul 29, 2021 | $1.38B |
| Mar 31, 2021 | $0.54 | $0.47 | $0.43 - $0.50 | +14.89% | Beat | +8.0% | 23 | N/A | Apr 20, 2021 | $1.22B |
| Dec 31, 2020 | $0.50 | $0.53 | $0.48 - $0.57 | -5.66% | Miss | +2.0% | 22 | N/A | Jan 27, 2021 | $1.19B |
| Sep 30, 2020 | $0.51 | $0.44 | $0.40 - $0.48 | +15.91% | Beat | +8.5% | 22 | N/A | Oct 21, 2020 | $1.14B |
| Jun 30, 2020 | $0.34 | $0.19 | -$0.19 - $0.27 | +78.95% | Beat | -26.1% | 21 | N/A | Jul 23, 2020 | $925.00M |
| Mar 31, 2020 | $0.50 | $0.41 | $0.30 - $0.53 | +21.95% | Beat | +13.6% | 20 | N/A | Apr 23, 2020 | $1.13B |
| Dec 31, 2019 | $0.49 | $0.50 | $0.48 - $0.52 | -2.00% | Miss | +25.6% | 20 | N/A | Jan 30, 2020 | $1.17B |
| Sep 30, 2019 | $0.47 | $0.41 | $0.40 - $0.42 | +14.63% | Beat | +30.6% | 21 | N/A | Oct 23, 2019 | $1.09B |
| Jun 30, 2019 | $0.46 | $0.44 | $0.43 - $0.46 | +4.55% | Beat | +12.2% | 22 | N/A | Jul 23, 2019 | $1.09B |
| Mar 31, 2019 | $0.44 | $0.41 | $0.39 - $0.44 | +7.32% | Beat | +7.3% | 22 | N/A | Apr 23, 2019 | $993.00M |
| Dec 31, 2018 | $0.39 | $0.39 | $0.38 - $0.41 | 0.00% | In line | +25.8% | 24 | N/A | Jan 31, 2019 | $977.70M |
| Sep 30, 2018 | $0.36 | $0.34 | $0.32 - $0.35 | +5.88% | Beat | +28.6% | 21 | N/A | Oct 23, 2018 | $906.60M |
| Jun 30, 2018 | $0.41 | $0.38 | $0.37 - $0.40 | +7.89% | Beat | +13.9% | 20 | N/A | Jul 26, 2018 | $943.70M |
| Mar 31, 2018 | $0.41 | $0.37 | $0.36 - $0.39 | +10.81% | Beat | +32.3% | 20 | N/A | Apr 24, 2018 | $894.80M |
| Dec 31, 2017 | $0.31 | $0.30 | $0.29 - $0.32 | +3.33% | Beat | +24.0% | 20 | N/A | Feb 1, 2018 | $888.50M |
| Sep 30, 2017 | $0.28 | $0.29 | $0.27 - $0.31 | -3.45% | Miss | +21.7% | 21 | N/A | Oct 24, 2017 | $821.50M |
| Jun 30, 2017 | $0.36 | $0.29 | $0.29 - $0.31 | +24.14% | Beat | +44.0% | 21 | N/A | Jul 26, 2017 | $841.80M |
| Mar 31, 2017 | $0.31 | $0.27 | N/A | +14.81% | Beat | +29.2% | N/A | N/A | Apr 25, 2017 | $883.50M |
| Dec 31, 2016 | $0.25 | $0.24 | N/A | +4.17% | Beat | +19.0% | N/A | N/A | Feb 1, 2017 | $767.70M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.56, down 2.3% from the year before. It was $0.97 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.56 | -2.3% |
| Dec 31, 2024 | $2.62 | +4.4% |
| Dec 31, 2023 | $2.51 | N/A |
| Dec 31, 2022 | $2.48 | +11.2% |
| Dec 31, 2021 | $2.23 | +20.5% |
| Dec 31, 2020 | $1.85 | N/A |
| Dec 31, 2019 | $1.86 | +18.5% |
| Dec 31, 2018 | $1.57 | +24.6% |
| Dec 31, 2017 | $1.26 | +29.9% |
| Dec 31, 2016 | $0.97 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,300 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,313 | 12 | |
| 2026Q2 | Jun 30, 2026 | 6,852 | 13 | |
| 2025Q4 | Dec 31, 2025 | 7,963 | 13 | |
| 2025Q3 | Sep 30, 2025 | 7,618 | 12 | |
| 2025Q2 | Jun 30, 2025 | 8,339 | 17 | |
| 2025Q1 | Mar 31, 2025 | 8,887 | 15 | |
| 2024Q4 | Dec 31, 2024 | 5,640 | 11 | |
| 2024Q3 | Sep 30, 2024 | 6,276 | 17 |
2026Q3 Earnings Call
Opening remarks
Gerianne Sarte Senior Vice President, Investor Relations Good afternoon, and thank you for joining us. With me on today's call is our CEO, Bernard Zovighian, and our CFO, Doretta Mistras. Also joining us for the Q&A portion of the call will be Dan Lippis, our Global Leader of TAVR, and Daveen Chopra, who has global responsibility for TMTT, Surgical, and IHFM. After the close of regular trading, Edwards Lifesciences released third quarter 2026 financial results. During today's call, management will discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions, and projections. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause these differences can be found in today's press release and Edwards' other SEC filings, all of which are available on the company's website at edwards.com. Unless otherwise noted, our commentary on sales growth refers to underlying sales growth, which is defined in the financial results press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during this call are also included in today's press release. Quarterly and full-year growth rates refer to continuing operations. With that, I'll turn the call over to Bernard for his comments.
Bernard Zovighian CEO Thank you, Gerianne, and welcome, everyone. We delivered third-quarter results that exceeded expectations, with both our businesses and regions driving strong, broad-based performance. Even more importantly, we achieved meaningful progress on several of our most important clinical, regulatory policy, and commercial priorities, strengthening our outlook for durable long-term growth. The consistency of our top-tier financial performance is a reflection of our focused strategy, as well as our commitment to innovation, speed and agility, and the strength of execution by our 17,000 dedicated employees across Edwards. Third-quarter sales of $1.72 billion grew 11.2%. This performance was driven by our structural heart portfolio, including continued strength in TAVR and growing contributions from our portfolio of TMTT therapies with PASCAL, EVOQUE, and SAPIEN M3. Based on our strong performance this quarter, we are raising our full-year sales growth guidance to approximately 11.5% and our adjusted EPS guidance to $2.97 to $3.05, growing 18% at the midpoint versus the prior year. As I reflect on 2026 so far, I am proud of what our teams have accomplished and how we are positioning Edwards for the future.
Frequently Asked Questions About EW
When is Edwards Lifesciences's next earnings date?
Edwards Lifesciences's next earnings report is expected for Feb 8, 2027.
Did EW beat earnings estimates last quarter?
Yes. Edwards Lifesciences reported EPS of $0.80 for the quarter ended Sep 30, 2026, above the $0.73 estimate, a 9.59% surprise.
What EPS do analysts expect from EW next quarter?
The consensus EPS estimate for Edwards Lifesciences for the quarter ending Dec 31, 2026 is $0.69 from 28 analysts, with estimates from $0.63 to $0.79.
How often does EW beat earnings estimates?
Edwards Lifesciences beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +6.45%.
EW pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts